Duligotuzumab
Based on 1 Customer Validation
Duligotuzumab (MEHD-7945A; RG 7597) is a humanized IgG-κ monoclonal antibody targeting EGFR. Duligotuzumab blocks the binding of ligands to these two receptors, inhibits downstream HER/ErbB, AKT and MAPK signaling pathways, induces antibody-dependent cellular cytotoxicity, reduces the proliferation and migration abilities of cancer cells, promotes apoptosis, exerts radiosensitizing effects, and reverses EGFR resistance in cancer cells. Duligotuzumab can be used in tumor-related research.
For research use only. We do not sell to patients.
- Purity : 98.70%
- CAS No.: 1314238-96-4
- Molecular Weight:144.78 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
All EGFR Isoforms
More
Biological Activity
Description
Isotype
Human IgG1 kappa
Recommend Isotype Controls
Species Reactivity
Human
IC50 & Target
[1]|
HER3 |
HER2 |
EGFR |
Akt |
p38 MAPK |
In Vitro
Duligotuzumab (0.01-25 μM; 72 h) inhibits proliferation of HER2-positive OE33, OE19, and NCI-N87 gastric cancer cell lines with IC50 values of ≈0.1 to ≈0.5 μM over 72 h, but has no effect on HER2-negative MKN28 gastric cancer cells[1].
Duligotuzumab (0.5 μM; 7 days) reduces colony formation in HER2-positive OE33, OE19, and NCI-N87 gastric cancer cell lines over 7 days[1].
Duligotuzumab (0.5 μM; 72 h) reduces migration of HER2-positive OE33, OE19, and NCI-N87 gastric cancer cell lines over 72 h[1].
Duligotuzumab (0.5 μM; 72 h) induces apoptosis in HER2-positive OE33, OE19, and NCI-N87 gastric cancer cell lines over 72 h, with an apoptotic rate of ≈35% in OE33 cells[1].
Duligotuzumab (0.5 μM; 48 h) reduces phosphorylated HER2 and HER3 levels but does not alter total or phosphorylated AKT, MAPK, or total HER2 or HER3 protein levels in HER2-positive OE33 and OE19 gastric cancer cell lines[1].
Duligotuzumab induces antibody-dependent cell-mediated cytotoxicity in EGFR-overexpressing cell lines, with activity comparable to cetuximab[2].
Duligotuzumab binds to EGFR with a dissociation constant of 0.4 nM[2].
Duligotuzumab enhances antiproliferative activity in cancer cells, overcomes EGFR resistance, and enhances radiation effects compared to monospecific HER antibodies, including in cetuximab-resistant cells[3].
Duligotuzumab potently blocks EGFR and HER3 receptors and inhibits downstream HER/ErbB signaling pathways in an in vitro system[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only. Further protocols information, click here.
-
Cell Line:HER2-positive human gastric cancer cell lines (OE33, OE19, NCI-N87), HER2-negative human gastric cancer cell line (MKN28)
-
Concentration:0.01, 0.05, 0.1, 0.5, 1, 5, 10, 25 μM
-
Incubation Time:72 h
-
Result:Inhibited proliferation of HER2-positive OE33, OE19, and NCI-N87 cells, with IC50 values ranging from ≈0.1 to ≈0.5 μM.
Exhibited no antiproliferative effect in HER2-negative MKN28 cells.
-
Cell Line:HER2-positive human gastric cancer cell lines (OE33, OE19, NCI-N87)
-
Concentration:0.5 μM
-
Incubation Time:72 h
-
Result:Reduced migration of OE33, OE19, and NCI-N87 cells, though to a lesser extent than the combination of Duligotuzumab and trastuzumab.
-
Cell Line:HER2-positive human gastric cancer cell lines (OE33, OE19, NCI-N87)
-
Concentration:0.5 μM
-
Incubation Time:72 h
-
Result:Induced apoptosis in OE33, OE19, and NCI-N87 cells, with OE33 cells showing an apoptotic rate of ≈35%.
-
Cell Line:HER2-positive human gastric cancer cell lines (OE33, OE19)
-
Concentration:0.5 μM
-
Incubation Time:48 h
-
Result:Had no effect on the expression of total or phosphorylated AKT and MAPK proteins in OE33 and OE19 cells.
Reduced phosphorylated HER2 and HER3 receptor levels in these cell lines, though not to the extent seen with the combination of Duligotuzumab and trastuzumab.
Did not alter total HER2 or HER3 receptor levels.
Gene ID
Accession
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
Human IgG1 kappa
Application
ELISA, FACS, Functional assay
Verified Bioactivity
-
Immobilized EGFR Protein, Human can bind Duligotuzumab. The EC50 for this effect is 4.244 ng/mL. -
Immobilized HER3 Protein, Human can bind Duligotuzumab. The EC50 for this effect is 1.423 ng/mL. -
Flow Cytometry analysis of Hela cells labelling EGFR (red) with Duligotuzumab (HY-P99866). Cells were fixed with 4% paraformaldehyde and permeabilised with 90% methanol. Then cells were stained with the primary antibody at 1/200 dilution for an hour at 4℃. Goat Anti-Human IgG H&L (AF488) (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG1 kappa (HY-P99001, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1314238-96-4
-
Appearance Liquid
-
Molecular Weight 144.78 kDa
-
Color Colorless to light yellow
-
SMILES
[Duligotuzumab]
-
Synonyms
MEHD-7945A; RG 7597
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Protocols
-
Apoptosis
Apoptosis, also called programmed cell death, is generally characterized by distinct morphological characteristics.
-
TUNEL staining for apoptotic DNA fragmentation
TUNEL staining detects DNA strand breaks by using terminal deoxynucleotidyl transferase to add labeled nucleotides to exposed 3′-OH DNA termini, generating either microscopic staining in fixed cells or tissue sections, or fluorescence/cytometric signal in cell suspensions. TUNEL positivity reflects DNA fragmentation but should not be interpreted alone as definitive apoptosis, because TUNEL can also label necrotic, autolytic, mechanically damaged, or DNA-repair-associated DNA breaks.
-
Cell Cytotoxicity Assay
Cytotoxicity assays are usually based on the assessment of cell membrane damage, which can also be indirectly detected by measuring cell viability. Detection methods include MTT assay, CKK-8 assay, LDH assay and ATP assay, etc.
-
Mammalian live/dead viability and cytotoxicity staining
Live/dead viability and cytotoxicity staining assays are based on the simultaneous detection of intracellular esterase activity in metabolically active (viable) cells and membrane integrity loss in non-viable cells. In commonly used dual-staining approaches, membrane-permeant fluorogenic substrates are converted by intracellular esterases into fluorescent products in live cells, while impermeant DNA-binding dyes selectively enter cells with compromised plasma membranes and label nucleic acids in dead or dying cells, enabling discrimination between viable and non-viable populations by fluorescence microscopy or flow cytometry.
-
Annexin V plus membrane-impermeant dye apoptosis staining
Annexin V-based apoptosis assays rely on the detection of phosphatidylserine (PS) externalization from the inner leaflet of the plasma membrane to the outer leaflet, an early biochemical hallmark of apoptosis. Fluorescently labeled Annexin V binds PS in a calcium-dependent manner, enabling identification of early apoptotic cells by flow cytometry or fluorescence microscopy. When combined with a membrane-impermeant DNA-binding dye (e. g. , propidium iodide), this approach allows discrimination between viable (Annexin V−/dye−), early apoptotic (Annexin V+/dye−), and late apoptotic or necrotic (Annexin V+/dye+) cell populations by assessing membrane integrity and PS exposure.
-
Cell migration
Cell migration is a method that plays an important role in wound healing, cell differentiation, embryonic development, etc.
-
Apoptosis Solutions
Apoptosis is a regulated, generally non-lytic cell-death pathway that removes unwanted, damaged, infected, or abnormal cells through coordinated morphological changes, caspase activation, DNA fragmentation, and membrane remodeling. The intrinsic apoptosis pathway is controlled mainly by mitochondrial outer membrane permeabilization, BCL-2 family proteins, cytochrome c release, apoptosome formation, caspase-9 activation, and downstream executioner caspase-3/7 activation. The extrinsic apoptosis pathway is initiated by death receptors such as Fas, TNFR, and TRAIL receptors, which recruit adaptor proteins and activate caspase-8 before engaging executioner caspases or mitochondrial amplification through BID cleavage. Apoptosis is linked to many phenotypes, including cancer cell killing, tissue homeostasis, immune regulation, neurodegeneration, infection response, and treatment-induced cytotoxicity; unresolved questions include how apoptosis interacts with necroptosis, pyroptosis, ferroptos
-
Cell Viability Determination by MTT Colorimetric Assay
The following protocol uses the MTT colorimetric assay as a classic literature-established method for assessing cell viability/metabolic activity in cultured mammalian cells. MTT[3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide] is reduced by metabolically active cells to a colored formazan product; the amount of formazan is quantified spectrophotometrically and provides an indirect measure of metabolically active viable cells. Importantly, MTT reduction reflects cellular oxidoreductase/metabolic activity rather than an absolute direct count of living cells, so changes in cellular metabolism can alter the signal independently of cell number.
Purity & Documentation
-
Data Sheet (265 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Laterza MM, et al. Enhanced Antitumor Effect of Trastuzumab and Duligotuzumab or Ipatasertib Combination in HER-2 Positive Gastric Cancer Cells. Cancers (Basel). 2021;13(10):2339. [Content Brief]
[2]. Fayette J, et al. Randomized Phase II Study of Duligotuzumab (MEHD7945A) vs. Cetuximab in Squamous Cell Carcinoma of the Head and Neck (MEHGAN Study). Front Oncol. 2016;6:232. [Content Brief]
[3]. Cole, P. DULIGOTUZUMAB. Drugs of the Future 2015, 40(3): 167-172.
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)